Stock VERV VERVE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Verve Therapeutics, Inc.

Equities

VERV

US92539P1012

Real-time Estimate Cboe BZX
Other stock markets
 14:38:40 2024-05-13 EDT 		5-day change 1st Jan Change
6.185 USD +2.91% Intraday chart for Verve Therapeutics, Inc. -3.20% -55.49%
05-08 Verve Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
05-07 Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Verve Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
CI
Sector Update: Health Care Stocks Slide Late Afternoon
MT
Top Midday Decliners
MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Tuesday
MT
Sector Update: Health Care
MT
Verve Therapeutics Pauses Heart-1 Trial After Serious Adverse Events; Shares Fall Pre-Bell
MT
Top Premarket Decliners
MT
Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels
RE
Verve Therapeutics, Inc. Announces Updates on its PCSK9 Program
CI
Verve Therapeutics Q4 Net Loss Widens, Collaboration Revenue Rises; Beats Estimates; Shares Rise
MT
Verve Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Verve Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
Google Ventures adds partner to back AI, open source startups
RE
Rate Outlooks Push Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday
MT
Verve Therapeutics, Inc. Presents Interim Data from Ongoing Heart-1 Phase 1B Clinical Trial of Verve-101
CI
Verve Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Eli Lilly to Acquire Beam Therapeutics' Opt-In Rights to Verve Therapeutics' Cardiovascular Programs
MT
Eli Lilly, Beam Sign Initial $250 Million Deal for Verve Rights
MT
Beam Therapeutics to Sell Rights in Verve Licensing Deal to Lilly for $250 Million Upfront
DJ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VERV Stock
  4. News Verve Therapeutics, Inc.
  5. Highlights
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW